|Summary sheet: Metizolam|
|Common names||Metizolam, Desmethyletizolam|
|Systematic name||4-(2-chlorophenyl)-2-ethyl-6H-thieno[3,2-f] [1,2,4]triazolo[4,3-a] [1,4]diazepine|
|Routes of Administration|
Metizolam (also known as Desmethyletizolam) is a synthetic depressant of the thienodiazepine chemical class that reportedly produces etizolam-like effects such as anxiety suppression, disinhibition, sedation, muscle relaxation and memory suppression when administered. It is half as potent and has a 60% longer half-life than etizolam.
This compound was patented in 1995 by a Japanese company as a medication for treating anxiety. Despite this, it has little to no history of human usage prior to its release as a grey area research chemical by online vendors in September 2015.
Similar to benzodiazepines, the sudden discontinuation of thienodiazepines can be potentially dangerous or life-threatening for individuals using regularly for extended periods of time, sometimes resulting in seizures or death. It is highly recommended to taper one's dose by gradually lowering the amount taken each day for a prolonged period of time instead of stopping abruptly.
- 1 Chemistry
- 2 Pharmacology
- 3 Subjective effects
- 4 Potentially dangerous interactions
- 5 Toxicity and harm potential
- 6 Preparation methods
- 7 Legal issues
- 8 See also
- 9 External links
- 10 References
Metizolam, or desmethyletizolam, is a structural relative of benzodiazepines whereby the benzene ring has been replaced by a thiophene ring, classifying it as a thienodiazepine. It differs structurally from its parent compound etizolam through the removal of the methyl group on the triazole ring.
Metizolam contains a thiophene ring fused to a diazepine ring, which is a seven member ring with the two nitrogen constituents located at R1 and R4. Thiophene is a five member aromatic ring with one sulfur atom. This forms the thienodiazepine core of metizolam. An ethyl chain is bound to this bicyclic structure at R7.
Additionally, an R2 chlorine-substituted phenyl ring is bound to this structure at R5. Metizolam also contains a triazole ring fused to and incorporating R1 and R2 of its diazepine ring. Deschloroetizolam shares this fused triazole ring substitution with certain benzodiazepine substances, called triazolobenzodiazepines (distinguished by the suffix "-zolam").
Thienzodiazepines produce a variety of effects by binding to the benzodiazepine receptor site and magnifying the efficiency and effects of the neurotransmitter gamma aminobutyric acid (GABA) by acting on its receptors. As this site is the most prolific inhibitory receptor set within the brain, its modulation results in the sedating (or calming effects) of metizolam on the nervous system.
Disclaimer: The effects listed below are taken from the subjective effect index, which is based on anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be treated with a healthy degree of skepticism. It is worth noting that these effects will rarely (if ever) occur all at once, although higher doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- Anxiety suppression
- Thought deceleration
- Analysis suppression
- Compulsive redosing
- Emotion suppression - Although this compound primarily suppresses anxiety, it also dulls other emotions in a manner which is distinct but less intensive than that of antipsychotics.
- Delusions of sobriety - This is the false belief that one is perfectly sober despite obvious evidence to the contrary such as severe cognitive impairment and an inability to fully communicate with others. It most commonly occurs at heavy dosages.
- Dream potentiation
Potentially dangerous interactions
Although many drugs are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
- Depressants (1,4-Butanediol, 2-methyl-2-butanol, alcohol, barbiturates, GHB/GBL, methaqualone, opioids) - This combination can result in dangerous or even fatal levels of respiratory depression. These substances potentiate the muscle relaxation, sedation and amnesia caused by one another and can lead to unexpected loss of consciousness at high doses. There is also an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
- Dissociatives - This combination can result in an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
- Stimulants - It is dangerous to combine thienzodiazepines with stimulants due to the risk of excessive intoxication. Stimulants decrease the sedative effect of benzodiazepines, which is the main factor most people consider when determining their level of intoxication. Once the stimulant wears off, the effects of thienzodiazepines will be significantly increased, leading to intensified disinhibition as well as other effects. If combined, one should strictly limit themselves to only dosing a certain amount of thienzodiazepines per hour. This combination can also potentially result in severe dehydration if hydration is not monitored.
Toxicity and harm potential
The toxicity and long-term health effects of recreational metizolam use have not been studied in any scientific context and the exact toxic dosage is unknown. This is because metizolam is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried metizolam suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
The lethal dosage of metizolam has not been established; however, (like many benzodiazepines) it has a large therapeutic index and margin of safety. Complications may arise when administered in excess as this compound has not been formally studied and has little to no history of human usage.
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
Thienzodiazepines are extremely addictive. Tolerance to the sedative-hypnotic effects develops within a couple of days of repeated administration. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). Metizolam presents cross-tolerance with all thienzodiazepines and benzodiazepines, meaning that after the consumption of metizolam all compounds of the same class will have a reduced effect.
Abrupt discontinuation of metizolam following regular dosing over several days can result in a withdrawal phase which includes rebound symptoms such as increased anxiety and insomnia. It is possible to gradually reduce the dose over the course of several days, which will lengthen the duration of the withdrawal period, but reduce the perceived intensity.
Thienzodiazepine discontinuation is notoriously difficult; it is potentially life-threatening for individuals using regularly to discontinue use without tapering their dose over a period of weeks. There is an increased risk of seizure following discontinuation. Drugs which lower the seizure threshold such as tramadol should be avoided during withdrawal.
Thienodiazepine overdose may occur when a thienodiazepine is taken in extremely heavy quantities or concurrently with other depressants. This is particularly dangerous with other GABAergic depressants such as barbiturates and alcohol since they work in a similar fashion, but bind to distinct allosteric sites on the GABAA receptor. Thus their effects potentiate one another. Thienodiazepines increase the frequency in which the chlorine ion pore opens on the GABAA receptor while barbiturates increase the duration in which they are open, meaning when both are consumed, the ion pore will open more frequently and stay open longer. Thienodiazepine overdose is a medical emergency that may lead to a coma, permanent brain injury or death if not treated promptly and properly.
Symptoms of a thienodiazepine overdose may include severe thought deceleration, slurred speech, confusion, delusions, respiratory depression, coma or death. Thienodiazepine overdoses may be treated effectively in a hospital environment, with generally favorable outcomes. Thienodiazepine overdoses are sometimes treated with flumazenil, a GABAA antagonist, however care is primarily supportive in nature.
Paradoxical reactions to benzodiazepines such as increased seizures (in epileptics), aggression, increased anxiety, violent behavior, loss of impulse control, irritability and suicidal behavior sometimes occur (although they are rare in the general population, with an incidence rate below 1%).
These paradoxical effects occur with greater frequency in recreational abusers, individuals with mental disorders, children, and patients on high-dosage regimes. Due to the close structural and pharmacological similarities they share, it is likely that these same risks apply to thienodiazepines as well.
- Volumetric liquid dosing - If one's thienodiazepines are in powder form, they are unlikely to weigh out accurately without the most expensive of scales due to their extreme potency. To avoid this, one can dissolve the thienodiazepine volumetrically into a solution and dose it accurately based upon the methodological instructions linked within this tutorial here.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
Metizolam is currently a grey area compound within most parts of the world. This means that it is not known to be specifically illegal within any country, but people may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume.
- Canada: All benzodiazepines are schedule IV in Canada. 
- Germany: ETH-LAD is controlled under the NpSG as of July 18, 2019.   Production and import for placing on the market and trade is punishable. Possession, although illegal, is not penalized if not intended for sale.
- Sweden: Following its sale as a designer drug, metizolam was made illegal in Sweden on 26 January 2016.
- United Kingdom: It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
- Metizolam (Wikipedia)
- Metizolam (Isomer Design)
- Metizolam (Bluelight)
- Metizolam (UK Chemical Research)
- Risks of Combining Depressants (Tripsit) | https://tripsit.me/combining-depressants/
- Heteroaromaten mit anellierten Siebenringen, III. Umwandlung von Thienotriazolooxazepinen in Diazepine | https://dx.doi.org/10.1002%2Fjlac.197819780806
- Triazolothienodiazepine compounds | http://www.google.com/patents/US3904641
- Thienylazole compound and thienotriazolodiazepine compound | http://www.google.com/patents/EP0776892A1
- Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain - Appendix B-6: Benzodiazepine Tapering | http://nationalpaincentre.mcmaster.ca/opioid/cgop_b_app_b06.html
- Benzodiazepine interactions with GABA receptors (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/6147796
- Twyman, R. E., Rogers, C. J., & Macdonald, R. L. (1989). Differential regulation of γ‐aminobutyric acid receptor channels by diazepam and phenobarbital. Annals of Neurology, 25(3), 213-220. https://doi.org/10.1002/ana.410250302
- Amrein, R., Leishman, B., Bentzinger, C., & Roncari, G. (1987). Flumazenil in benzodiazepine antagonism. Medical Toxicology and Adverse Drug Experience, 2(6), 411-429. PMID: 8306565
- Mancuso, C. E., Tanzi, M. G., & Gabay, M. (2004). Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 24(9), 1177-1185. https://doi.org/10.1592/phco.24.13.1177.38089
- Paton, C. (2002). Benzodiazepines and disinhibition: a review. The Psychiatrist, 26(12), 460-462. https://doi.org/10.1192/pb.26.12.460
- Bond, A. J. (1998). Drug-induced behavioural disinhibition. CNS Drugs, 9(1), 41-57. https://doi.org/10.2165/00023210-199809010-00005
- Drummer, O. H. (2002). Benzodiazepines-Effects on Human Performance and Behavior. Forensic Science Review, 14(1-2), 1-14. PMID: 26256485
- (in Swedish) Folkhälsomyndigheten. | https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2016/januari/31-nya-substanser-klassas-som-narkotika-eller-halsofarlig-vara/
- Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted